Pesg report: silexion therapeutics' systemic delivery breakthrough positions company as rising star in the multi-billion dollar precision oncology market

New york--(business wire)---- $slxn #biotech--pesg research releases new market update: silexion therapeutics (nasdaq: slxn)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of sil-204, potentially opening new frontiers in treating kras-driven cancers. this development comes amid increasing industry appetite for innovative oncology assets, exemplified by recent multi-billion dollar acquisitions. silexion's latest precli.
SGU Ratings Summary
SGU Quant Ranking